{
    "root": "ba6ae57f-0729-4c8d-afc8-1e99a5a99871",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "VITRAKVI",
    "value": "20250430",
    "ingredients": [
        {
            "name": "LAROTRECTINIB",
            "code": "PF9462I9HX"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SODIUM PHOSPHATE",
            "code": "SE337SVY37"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "POTASSIUM SORBATE",
            "code": "1VPU26JZZ4"
        },
        {
            "name": "ADRABETADEX",
            "code": "8W6Q67R6NX"
        },
        {
            "name": "HYDROXYPROPYL BETADEX",
            "code": "1I96OHX6EK"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        }
    ],
    "indications": "VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:\n                  \n                  \n                     \n                        have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,\n                     \n                     \n                        are metastatic or where surgical resection is likely to result in severe morbidity, and \n                     \n                     \n                        have no satisfactory alternative treatments or that have progressed following treatment.\n                     \n                  \n                  \n                     Select patients for therapy based on an FDA-approved test [see Dosage and Administration (2.1)].",
    "contraindications": "Select patients for treatment with VITRAKVI based on the presence of a NTRK gene fusion ( 2.1 , 14 ). Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of 1 Meter-Squared or greater: 100 mg orally twice daily ( 2.2 ) Recommended Dosage in Pediatric Patients with Body Surface Area of Less Than 1 Meter-Squared: 100 mg/m 2 orally twice daily ( 2.2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "None."
}